What question did this study set out to answer?

The aim is to assess patient characteristics and healthcare resource utilization in multiple myeloma treated with CAR-T cell therapies.

December 8, 2025BloodOpen Access

Chimeric antigen receptor T cells in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort study reveals healthcare resource utilization and ICU needs in multiple myeloma patients treated with CAR-T therapies.

The aim is to assess patient characteristics and healthcare resource utilization in multiple myeloma treated with CAR-T cell therapies.
Retrospective cohort study using IQVIA PharMetrics Plus database
Included adults with multiple myeloma receiving ide-cel or cilta-cel
Evaluated demographics, administration-related HCRU, and post-administration HCRU
89 patients received ide-cel and 144 patients received cilta-cel
Commonly administered in inpatient settings with average stays of approximately 2 weeks
Cytokine release syndrome and hematologic complications were observed in significant percentages of patients

Niehoff et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort study reveals healthcare resource utilization and ICU needs in multiple myeloma patients treated with CAR-T therapies.